Drug delivery devices and methods

• US 20040034338A1
• Filed: 08/07/2003
• Published: 02/19/2004
• Est. Priority Date: 08/07/2002
• Status: Abandoned Application

• Current Assignee: Ams Research Corporation (Endo International PLC)
• Original Assignee: Ams Research Corporation (Endo International PLC)
• Inventors: Grant, Robert C., Thierfelder, Christopher A.
• Application Number:
  US10/636,182
• Publication Number:
  US 20040034338A1
• Time in Patent Office: Days
• US Class Current: 604/891.1
• CPC Class Codes: A61K 47/20 containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00

Abstract

Implantable drug delivery devices and components are disclosed. The devices may be implanted in a wide variety of locations in a patient'"'"'s anatomy. Novel methods for treating a variety of disorders are also disclosed.

Claims

1. An implantable drug delivery system comprising:

a housing suitable for implantation in a patient;

storage means for storing a quantity of drug in a dry powder form,

metering means for metering a predetermined, effective amount of the drug; and

delivery means for delivering an effective amount of the drug to a patient to treat a disorder.

2. An implantable drug delivery system according to claim 1 wherein the delivery means comprises:

a catheter having a plurality of drug delivery ports, the drug delivery ports being movable between an open position to deliver the drug to the patient, and a closed position; and

drug delivery path preservation means for resisting fibrous occlusion of the drug delivery ports.

3. An implantable drug delivery system comprising:

a housing suitable for implantation in a patient,

a storage chamber for storing a quantity of drug,

metering means for metering a predetermined, effective amount of the drug; and

delivery means for delivering an effective amount of the drug to a patient to treat a disorder.

4. An implantable drug delivery system according to claim 3 wherein the storage means

comprises a plurality of storage compartments,

the metering means comprises a plurality of micro-channels capable of communicating with the storage compartments, a mixing chamber, and valve means capable of being opened to afford fluid communication with the storage compartments.

5. An implantable drug delivery system according to claim 4 further comprising indexing means for affording indexed communication between the mixing chamber and a micro-channel.

6. An implantable drug delivery system according to claim 3 wherein the drug comprises prostaglandin E1.

7. An implantable drug delivery system according to claim 3 wherein the system includes

a catheter with drug delivery ports that are sized and shaped to be implanted in a corporal body region of the patient.

8. An implantable drug delivery system according to claim 7 wherein the catheter includes a coating of poly(glycine-valine-glycine-valine-proline).

9. An implantable drug delivery system according to claim 3 wherein the device includes a drug delivery port, and

storage means for a substance for resisting fibrous occlusion of the drug delivery port.

10. An implantable drug delivery system according to claim 9 wherein the substance for resisting fibrous occlusion comprises a biodegradable polymer.

11. An implantable drug delivery system according to claim 3 wherein the delivery means comprises a pump.

12. An implantable drug delivery system according to claim 4 wherein the valve means are battery powered.

13. An implantable drug delivery system comprising:

storage means for storing a drug,

metering means for metering a predetermined, effective amount of the drug;

delivery means for delivering an effective amount of the drug to a patient to treat a disorder, the delivery means comprising;

a catheter having a plurality of drug delivery ports, the drug delivery ports being movable between an open position to deliver the drug to the patient, and a closed position; and

drug delivery path preservation means for resisting fibrous occlusion of the drug delivery ports.

14. An implantable drug delivery system according to claim 13, wherein the drug delivery path preservation means comprises poly(glycine-valine-glycine-valine-proline) associated with the catheter.

15. A drug delivery system according to claim 13, wherein the catheter has a longitudinal axis and the drug delivery ports comprise a plurality of slits.

16. An implantable drug delivery system according to claim 13, wherein the drug delivery path preservation means comprises a means for delivering a substance for resisting fibrous occlusions through the drug delivery ports.

17. An implantable drug delivery system according to claim 13, wherein the drug delivery path preservation means comprises a fluid coating on the catheter.

18. An implantable drug delivery system according to claim 13, wherein the drug delivery path preservation means comprises a film on the catheter.

20. A method of treating erectile dysfunction according to claim 17 further comprising resisting chances of an overdose of the prostaglandin E1 by preventing actuation of the device outside predetermined parameters.

19. A method of treating erectile dysfunction comprising the steps of:

implanting a supply of prostaglandin E1 in the body in a device capable of releasing a dose on demand, and

thereafter treating the erectile dysfunction by releasing an effective amount of prostaglandin E1 on demand of the patient.